Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Nasopharyngeal Carcinoma 14Triple Negative Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Squamous Cell Carcinoma 8Breast Neoplasms 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Small Cell Lung Carcinoma 6Neoplasms 6Advanced Solid Tumor 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Recurrence 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Solid Tumor 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Turcot syndrome 2Sarcoma 2Oropharyngeal Neoplasms 2Nasopharyngeal Neoplasms 2NSCLC 2Muscle Invasive Bladder Cancer (MIBC) 2Carcinoma, Squamous Cell 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2

Interventions

toripalimab 1Premedication 1Injections 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignant Solid Tumors × toripalimab × 1 year × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡